<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04635527</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI318F101</org_study_id>
    <nct_id>NCT04635527</nct_id>
  </id_info>
  <brief_title>A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase Ib Study to Evaluate the Safety and Efficacy of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase Ib study is to assess the safety, tolerability and effectiveness of&#xD;
      IBI318 in combination with conventional TACE (cTACE) in patients with potentially resected&#xD;
      hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 26, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing clinical and laboratory adverse events (AEs)</measure>
    <time_frame>Up to 90 days post last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with pathological Complete Response (pCR) after liver resection</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with major pathological response (MPR) after liver resection</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with R0 resection</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) in two arms based on mRECIST by investigator</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS) in two arms based on mRECIST by investigator</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in two arms</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>IBI318 combined with conventional TACE (cTACE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo combined with conventional TACE (cTACE)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI318</intervention_name>
    <description>before surgery IBI318 intravenous injection Q2W,after surgery IBI318 intravenous injection Q4W</description>
    <arm_group_label>IBI318 combined with conventional TACE (cTACE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cTACE</intervention_name>
    <description>conventional transarterial chemoembolization</description>
    <arm_group_label>IBI318 combined with conventional TACE (cTACE)</arm_group_label>
    <arm_group_label>Placebo combined with conventional TACE (cTACE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>before surgery placebo intravenous injection Q2W,after surgery placebo intravenous injection Q4W</description>
    <arm_group_label>Placebo combined with conventional TACE (cTACE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged ≥ 18 years and ≤ 75 years at the time of consent.&#xD;
&#xD;
          2. Hepatocellular carcinoma confirmed by histology/cytology.&#xD;
&#xD;
          3. Lesions with measurable disease at baseline by mRECIST.&#xD;
&#xD;
          4. Barcelona Clinic Liver Cancer stage A or B for hepatocellular carcinoma exceeding&#xD;
             Milan criteria.&#xD;
&#xD;
          5. Child-Pugh: &lt;=6&#xD;
&#xD;
          6. Adequate organ and bone marrow function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma,&#xD;
             cholangiocarcinoma components in tumor tissues.&#xD;
&#xD;
          2. Having previously received standard systemic therapy, ablative therapy, interventional&#xD;
             therapy and surgical treatment for hepatocellular carcinoma.&#xD;
&#xD;
          3. Potential liver transplant candidates&#xD;
&#xD;
          4. Have a history of hepatic encephalopathy or have a history of liver transplantation.&#xD;
&#xD;
          5. With clinical symptoms requires drainage of pleural effusion, ascites or pericardial&#xD;
             effusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaodong Sun</last_name>
    <phone>0512-69566088</phone>
    <email>xiaodong.sun@innoventbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tingbo Liang</last_name>
      <phone>0571-87236666</phone>
      <email>liangtingbo@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 22, 2020</last_update_submitted>
  <last_update_submitted_qc>November 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

